Genome Insight Launches Genome-Based Cancer Diagnosis 'CancerVision' in the US

Genome Insight announced on the 9th that it has officially launched ‘CancerVision,’ a whole genome sequencing (WGS)-based precision cancer diagnostic service, in the United States.

Genome Insight company logo [Photo by Genome Insight]

CancerVision is a diagnostic service that provides medical professionals with comprehensive information on cancer mutations through WGS analysis of cancer tissues, enabling its application in the diagnosis and treatment of actual cancer patients. Genome Insight plans to actively enter the U.S. market centered on its newly established U.S. subsidiary in San Diego, California.

Youngseok Joo, co-CEO of Genome Insight, explained, “Currently, doctors at major U.S. medical centers rely on partial panel tests (NGS) to determine treatment strategies, but the data is incomplete, resulting in insufficient useful information or the need for additional tests, which consumes time and costs. WGS, which could solve this problem, has not been a practical option for cancer diagnosis so far due to the data being too vast, complex, and expensive.”

Accordingly, through CancerVision, developed based on large-scale bioinformatics, computing analysis, and medical expertise, cancer genome information is summarized in detail and presented intuitively to doctors in an easy-to-understand and practical manner, making WGS user-friendly and applicable to precision cancer diagnosis and treatment. CEO Joo stated, “CancerVision, which offers WGS capabilities at an affordable cost, will change the paradigm of cancer diagnosis and treatment.”

CancerVision is said to rapidly and accurately detect genetic variations including ▲point mutations ▲structural variations ▲gene fusions related to FDA-approved drugs. Additionally, it can be used for further genomic discoveries related to personalized treatment approaches and applicable clinical studies that may assist future stages. The company also stated that CancerVision enables a comprehensive approach to ▲tumor mutation burden ▲mutation signatures ▲hereditary germline polymorphisms, which can enhance medical professionals’ decision-making processes.

Jehee Seo, CEO of Genome Insight, said, “Genome Insight is a physician-centered company that utilizes computing expertise to apply critical data for precision cancer diagnosis in real-time to actual environments in the fields of cancer and rare diseases.” She added, “Genome Insight’s goal is to analyze genomic data from over one million cancer patients to advance understanding of cancer and improve the effectiveness of cancer treatment.”

This content was produced with the assistance of AI translation services.